Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.50 |
| ▸ | DRD3 | P35462 | 8/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1726247 | 0.80 | DRD2 (0.53) | DRD2DRD3HTR1DHTR1BHTR1A | |
| SCHEMBL1726523 | 0.77 | DRD2 (0.50) | DRD2DRD3HTR1DHTR1BHTR1A | |
| SCHEMBL9752129 | 0.74 | DRD2 (0.65) | DRD2DRD3HTR1ADRD4 | |
| SCHEMBL30612423 | 0.73 | DRD2 (0.55) | DRD2DRD3HTR1DHTR1BHTR1A | |
| SCHEMBL29113476 | 0.73 | DRD2 (0.55) | DRD2DRD3HTR1DHTR1BHTR1A | |
| SCHEMBL1724591 | 0.73 | DRD2 (0.52) | DRD2DRD3HTR1DHTR1BHTR1A | |
| SCHEMBL16868763 | 0.72 | MCHR1 (0.41) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL16868783 | 0.72 | MCHR1 (0.41) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL16868778 | 0.72 | MCHR1 (0.41) | DRD2DRD3HTR1DHTR1BDRD4 | |
| SCHEMBL16868798 | 0.72 | MCHR1 (0.41) | DRD2DRD3HTR1DHTR1BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| EP-2403854-B1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | GRUENENTHAL GMBH (DE) | 2013-09-11 | — | — | EP | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| US-8158628-B2 | Sulfonylated 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine compounds and their use as pharmaceuticals | GRUENENTHAL GMBH (DE) | 2012-04-17 | — | — | US | disclosed |
| EP-2403854-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2012-01-11 | — | — | EP | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | GRUENETHAL GMBH (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010099938-A1 | SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS | Grünenthal GmbH (DE) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234387-A1 | Sulfonylated Tetrahydroazolopyrazines and their Use as Pharmaceuticals | BDKRB1, BDKRB2, KCNB1 | DRD2 834/4885DRD3 816/4885HTR1D 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.